These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

541 related articles for article (PubMed ID: 35690723)

  • 41. New drugs targeting calcitonin gene-related peptide for the management of migraines.
    Tana C; Cipollone F; Giamberardino MA; Martelletti P
    Expert Opin Emerg Drugs; 2023 Dec; 28(4):233-240. PubMed ID: 37996401
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Erenumab in the treatment of migraine.
    Jain S; Yuan H; Spare N; Silberstein SD
    Pain Manag; 2018 Nov; 8(6):415-426. PubMed ID: 30235976
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Targeting calcitonin gene-related peptide: a new era in migraine therapy.
    Charles A; Pozo-Rosich P
    Lancet; 2019 Nov; 394(10210):1765-1774. PubMed ID: 31668411
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treatment patterns for patients initiating novel acute migraine specific medications (nAMSMs) in the context of monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway.
    Zhou Z; Urman R; Gill K; Park AS; Vuvu F; Patel LB; Lu J; Wade RL; Frerichs L; Bensink ME
    J Headache Pain; 2023 Nov; 24(1):153. PubMed ID: 37946113
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies in Migraine: Focus on Drug Interactions.
    Janković SM; Janković SV
    Eur J Drug Metab Pharmacokinet; 2024 May; 49(3):263-275. PubMed ID: 38457093
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Role of CGRP in Migraine.
    Edvinsson L
    Handb Exp Pharmacol; 2019; 255():121-130. PubMed ID: 30725283
    [TBL] [Abstract][Full Text] [Related]  

  • 47. How to integrate monoclonal antibodies targeting the calcitonin gene-related peptide or its receptor in daily clinical practice.
    Tiseo C; Ornello R; Pistoia F; Sacco S
    J Headache Pain; 2019 May; 20(1):49. PubMed ID: 31060490
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.
    Berman G; Croop R; Kudrow D; Halverson P; Lovegren M; Thiry AC; Conway CM; Coric V; Lipton RB
    Headache; 2020 Sep; 60(8):1734-1742. PubMed ID: 32799325
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effectiveness of anti-CGRP monoclonal antibodies on central symptoms of migraine.
    Iannone LF; De Cesaris F; Ferrari A; Benemei S; Fattori D; Chiarugi A
    Cephalalgia; 2022 Nov; 42(13):1323-1330. PubMed ID: 35775208
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Erenumab in highly therapy-refractory migraine patients: First German real-world evidence.
    Scheffler A; Messel O; Wurthmann S; Nsaka M; Kleinschnitz C; Glas M; Naegel S; Holle D
    J Headache Pain; 2020 Jul; 21(1):84. PubMed ID: 32620151
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CGRP ligand and receptor monoclonal antibodies for migraine prevention: Evidence review and clinical implications.
    Dodick DW
    Cephalalgia; 2019 Mar; 39(3):445-458. PubMed ID: 30661365
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway.
    Waliszewska-Prosół M; Martelletti P
    Dent Med Probl; 2024; 61(1):9-11. PubMed ID: 38284301
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The efficacy and safety of calcitonin gene-related peptide monoclonal antibody for episodic migraine: a meta-analysis.
    Zhu Y; Liu Y; Zhao J; Han Q; Liu L; Shen X
    Neurol Sci; 2018 Dec; 39(12):2097-2106. PubMed ID: 30182284
    [TBL] [Abstract][Full Text] [Related]  

  • 54. CGRP, Amylin, Immunology, and Headache Medicine.
    Taylor FR
    Headache; 2019 Jan; 59(1):131-150. PubMed ID: 30390312
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: a real-world evidence observational study.
    Torres-Ferrús M; Gallardo VJ; Alpuente A; Caronna E; Gine-Cipres E; Pozo-Rosich P
    J Neurol; 2021 Oct; 268(10):3789-3798. PubMed ID: 33772636
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmaceutical aspects of novel CGRP inhibitors used in the prophylaxis and treatment of migraine.
    Jinesh S
    Inflammopharmacology; 2023 Oct; 31(5):2245-2251. PubMed ID: 37421480
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: A systematic review and network meta-analysis of phase 3 randomised controlled trials.
    Haghdoost F; Puledda F; Garcia-Azorin D; Huessler EM; Messina R; Pozo-Rosich P
    Cephalalgia; 2023 Apr; 43(4):3331024231159366. PubMed ID: 36855951
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Open-label trials for CGRP-targeted drugs in migraine prevention: A narrative review.
    Raffaelli B; De Icco R; Corrado M; Terhart M; Ailani J
    Cephalalgia; 2023 Feb; 43(2):3331024221137091. PubMed ID: 36718044
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Calcitonin gene-related peptide in migraine: from pathophysiology to treatment.
    Santos-Lasaosa S; Belvís R; Cuadrado ML; Díaz-Insa S; Gago-Veiga A; Guerrero-Peral AL; Huerta M; Irimia P; Láinez JM; Latorre G; Leira R; Pascual J; Porta-Etessam J; Sánchez Del Río M; Viguera J; Pozo-Rosich P
    Neurologia (Engl Ed); 2022 Jun; 37(5):390-402. PubMed ID: 35672126
    [TBL] [Abstract][Full Text] [Related]  

  • 60. New migraine prophylactic drugs: Current evidence and practical suggestions for non-responders to prior therapy.
    Lee MJ; Al-Karagholi MA; Reuter U
    Cephalalgia; 2023 Feb; 43(2):3331024221146315. PubMed ID: 36759320
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.